Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-11-19

Clinical Trial Update: MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED) [Phase 3]

View source ↗

Summary

A Phase 3 trial of maraviroc (MK0518) in HIV-infected patients switched from a protease inhibitor regimen was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Maraviroc (maraviroc)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: TERMINATED | Results posted: 2009-11-19